Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Whole Body Vibration Therapy in Boys With Duchenne Muscular Dystrophy

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Dr. Leanne Ward, Children's Hospital of Eastern Ontario Identifier:
First received: September 13, 2013
Last updated: February 21, 2017
Last verified: February 2017
Whole-body vibration therapy (WBVT) is a novel, non-pharmacological intervention aimed at improving muscle strength and endurance as well as bone density. It holds promise for children with neuromuscular disorders such as Duchenne muscular dystrophy (DMD) since muscle weakness results not only from muscle breakdown but also physical inactivity and muscle disuse atrophy. Weak DMD patients may increasingly limit their physical activity due to fear of falling or loss of independence (e.g. difficulty rising to stand without assistance). Prolonging the length of time boys with DMD are ambulatory is important for delaying complications of this disease (lung hypoventilation, scoliosis) as well as maintaining bone health. We propose to conduct a pilot study of WBVT in young boys with Duchenne muscular dystrophy (DMD). The primary outcome will be to document safety and feasibility of WBVT in this patient population. The secondary outcomes will evaluate changes in muscle strength and endurance. Bone health will also be examined as part of routine clinical care. The study will include 20 ambulatory boys with DMD; patients will be randomized (1:1 allocation) into 2 groups: WBVT treatment or no WBVT treatment (controls). Treatment groups will consist of 10 boys undergoing daily WBVT in an 8-week, open-label trial.

Condition Intervention
Duchenne Muscular Dystrophy
Device: Whole Body Vibration Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Children's Hospital of Eastern Ontario:

Primary Outcome Measures:
  • Assess the safety of using whole body vibration therapy in boys with Duchenne muscular dystrophy. To assess whether whole body vibration therapy can improve muscle strength and prolong ambulation from baseline to 8 weeks of therapy. To asses. [ Time Frame: 8 weeks ]
    Is WBVT safe, convenient and well-tolerated when administered daily to ambulatory to boys with DMD?

Secondary Outcome Measures:
  • Does WBVT result in any change in muscle strength. [ Time Frame: 8 weeks ]
    Does WBVT results in any measurable change in muscle strength measured by the maximum resistance of deltoid, hip flexor and knee extensor (measured with microFET2 dynamometer) and grip strength (measured by Jamar hand-held dynamometer)

  • Does WBVT result in any muscle function change. [ Time Frame: 8 weeks ]
    Does WBVT results in any measurable change in muscle function as measured by timed functional testing (timed 10m walk test; timed 4-stair climb; timed Gower manoeuvre, 6-minute walk test)?

  • Does WBVT result in any measurable change in muscle endurance. [ Time Frame: 8 weeks ]
    Does WBVT result in any measurable change in muscle endurance (total number of steps taken each day, measured by pedometer)?

  • Quality of life changes. [ Time Frame: 8 weeks ]
    Does WBVT result in any change in patient and family reported quality of life report? Measured by the Peds Q of L questionnaire.

  • Gait changes. [ Time Frame: 8 weeks ]
    Does WBVT result in any change in patient's gait (as measured by Gangway gait analysis and Leonardo force plate analysis)

  • Bone health [ Time Frame: 8 weeks ]
    Does WBVT result in any change in bone health indices (as measured by pQCT and routine skeletal imaging)

Enrollment: 4
Study Start Date: March 2013
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Whole Body Vibration Therapy
Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
Device: Whole Body Vibration Therapy
No Intervention: Control group
Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.


Ages Eligible for Study:   8 Years to 14 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of Duchenne muscular dystrophy confirmed by at least one of the following:

    • Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical presentation consistent with typical DMD
    • Positive gene deletion test (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as "out-of-frame", and clinical presentation consistent with typical DMD
    • Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) definitively associated with DMD, and clinical presentation consistent with typical DMD
  2. Age between 5 - 14 yrs old (inclusive)
  3. Positive Gower sign (indicating ability to rise from the floor & presence of proximal muscle weakness).
  4. Able to walk 10 meters in <12 seconds
  5. Able to stand upon WBVT plate (with knees flexed) for entire treatment protocol (i.e. 15-minutes)
  6. Stable absolute dose of glucocorticoids (i.e. prednisone or deflazacort) for at least 3 months prior
  7. Stable absolute doses of all medication that may affect muscle function (i.e. coenzyme Q10, green tea extract, creatine, arginine, glutamine, nutritional supplements, etc.) for at least 3 months prior
  8. Stable absolute dose of all medication that may affect bone metabolism (i.e. vitamin D and calcium supplementation) for at least 3 months prior

Exclusion Criteria:

  1. Clinical presentation, genetic testing and/or muscle biopsy consistent with Becker muscular dystrophy
  2. History of recent surgery (within past 6-months)
  3. History of a recent fracture (long-bone or vertebral) within past 6-months.
  4. Acute inflammatory processes of lower extremities (e.g. cellulitis, etc) due to risk of pain and/or worsening inflammatory process
  5. History of venous thrombosis (theoretically risk of inducing thromboembolic event).
  6. History of kidney or bladder stones
  7. History of uncontrolled seizures or severe migraines
  8. History of cardiac arrhythmia
  9. Intracranial pathology or hardware (e.g. ventriculoperitoneal shunt, cochlear implant).
  10. Use of any investigational or experimental products within last 6-months and/or concomitant participation in another study
  11. Inability or refusal to follow the study requirements (e.g. autism, severe cognitive or behaviour problems)
  12. Inability or refusal to provide informed consent (parent) and/or assent (child)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01954940

Canada, Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H 8L1
Sponsors and Collaborators
Children's Hospital of Eastern Ontario
Principal Investigator: Leanne Ward, MD Children's Hospital of Eastern Ontario
  More Information

Responsible Party: Dr. Leanne Ward, MD, Children's Hospital of Eastern Ontario Identifier: NCT01954940     History of Changes
Other Study ID Numbers: # 12/17E
Study First Received: September 13, 2013
Last Updated: February 21, 2017

Keywords provided by Children's Hospital of Eastern Ontario:
Whole body vibration therapy, muscle strength testing, bone health, ambulatory, endurance.

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked processed this record on May 25, 2017